Header cover image

Swiss Biotech Stocks

Results

16

0 new

Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.

16 companies

Roche Holding

Market Cap: CHF 281.6b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

ROG

CHF 329.90

7D

0.5%

1Y

24.8%

Novartis

Market Cap: CHF 214.0b

Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

NOVN

CHF 111.52

7D

1.8%

1Y

23.4%

Galderma Group

Market Cap: CHF 39.3b

Operates as a dermatology company worldwide.

GALD

CHF 165.60

7D

2.2%

1Y

56.5%

Sandoz Group

Market Cap: CHF 25.4b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

SDZ

CHF 58.88

7D

1.8%

1Y

56.5%

Bachem Holding

Market Cap: CHF 4.6b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

BANB

CHF 60.95

7D

1.8%

1Y

1.9%

Siegfried Holding

Market Cap: CHF 3.4b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

SFZN

CHF 76.60

7D

2.7%

1Y

-23.3%

Tecan Group

Market Cap: CHF 1.8b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

TECN

CHF 138.20

7D

7.5%

1Y

-35.5%

Cosmo Pharmaceuticals

Market Cap: CHF 1.7b

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 109.00

7D

3.6%

1Y

69.0%

Kuros Biosciences

Market Cap: CHF 1.1b

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

KURN

CHF 27.26

7D

-0.8%

1Y

9.0%

Idorsia

Market Cap: CHF 924.1m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.

IDIA

CHF 3.70

7D

-13.0%

1Y

313.6%

PolyPeptide Group

Market Cap: CHF 806.6m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

PPGN

CHF 24.45

7D

-6.3%

1Y

-17.1%

Basilea Pharmaceutica

Market Cap: CHF 654.9m

A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

BSLN

CHF 53.30

7D

-2.6%

1Y

24.7%

Newron Pharmaceuticals

Market Cap: CHF 499.0m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

NWRN

CHF 25.00

7D

4.8%

1Y

179.3%

Xlife Sciences

Market Cap: CHF 145.3m

Focuses on the development and commercialization of research projects in the life sciences sector.

XLS

CHF 25.20

7D

2.0%

1Y

5.4%

BioVersys

Market Cap: CHF 133.9m

A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.

BIOV

CHF 22.90

7D

-6.1%

1Y

n/a

Molecular Partners

Market Cap: CHF 130.1m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

MOLN

CHF 3.48

7D

2.8%

1Y

-29.5%